<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;fc=20230708114047&amp;ff=20241201090916&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;fc=20230708114047&amp;ff=20241201090916&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sun, 01 Dec 2024 14:09:18 +0000</lastbuilddate>
<pubDate>Fri, 29 Nov 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Data science from EuroHeart: a job in hand</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39612912/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241201090916&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 29:ehae819. doi: 10.1093/eurheartj/ehae819. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39612912/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241201090916&v=2.18.0.post9+e462414">39612912</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae819>10.1093/eurheartj/ehae819</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39612912</guid>
<pubDate>Fri, 29 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Adam Timmis</dc:creator>
<dc:date>2024-11-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Data science from EuroHeart: a job in hand</dc:title>
<dc:identifier>pmid:39612912</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae819</dc:identifier>
</item>
<item>
<title>Proteolethargy is a pathogenic mechanism in chronic disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39610243/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241201090916&amp;v=2.18.0.post9+e462414
      <description>The pathogenic mechanisms of many diseases are well understood at the molecular level, but there are prevalent syndromes associated with pathogenic signaling, such as diabetes and chronic inflammation, where our understanding is more limited. Here, we report that pathogenic signaling suppresses the mobility of a spectrum of proteins that play essential roles in cellular functions known to be dysregulated in these chronic diseases. The reduced protein mobility, which we call proteolethargy, was...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 25:S0092-8674(24)01274-1. doi: 10.1016/j.cell.2024.10.051. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The pathogenic mechanisms of many diseases are well understood at the molecular level, but there are prevalent syndromes associated with pathogenic signaling, such as diabetes and chronic inflammation, where our understanding is more limited. Here, we report that pathogenic signaling suppresses the mobility of a spectrum of proteins that play essential roles in cellular functions known to be dysregulated in these chronic diseases. The reduced protein mobility, which we call proteolethargy, was linked to cysteine residues in the affected proteins and signaling-related increases in excess reactive oxygen species. Diverse pathogenic stimuli, including hyperglycemia, dyslipidemia, and inflammation, produce similar reduced protein mobility phenotypes. We propose that proteolethargy is an overlooked cellular mechanism that may account for various pathogenic features of diverse chronic diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39610243/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241201090916&v=2.18.0.post9+e462414">39610243</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.051>10.1016/j.cell.2024.10.051</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39610243</guid>
<pubDate>Fri, 29 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Alessandra Dall'Agnese</dc:creator>
<dc:creator>Ming M Zheng</dc:creator>
<dc:creator>Shannon Moreno</dc:creator>
<dc:creator>Jesse M Platt</dc:creator>
<dc:creator>An T Hoang</dc:creator>
<dc:creator>Deepti Kannan</dc:creator>
<dc:creator>Giuseppe Dall'Agnese</dc:creator>
<dc:creator>Kalon J Overholt</dc:creator>
<dc:creator>Ido Sagi</dc:creator>
<dc:creator>Nancy M Hannett</dc:creator>
<dc:creator>Hailey Erb</dc:creator>
<dc:creator>Olivia Corradin</dc:creator>
<dc:creator>Arup K Chakraborty</dc:creator>
<dc:creator>Tong Ihn Lee</dc:creator>
<dc:creator>Richard A Young</dc:creator>
<dc:date>2024-11-29</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Proteolethargy is a pathogenic mechanism in chronic disease</dc:title>
<dc:identifier>pmid:39610243</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.051</dc:identifier>
</item>
<item>
<title>Handle with care, proceed with caution: do frail patients presenting with acute coronary syndrome benefit from revascularization?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39607800/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241201090916&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 28:ehae623. doi: 10.1093/eurheartj/ehae623. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39607800/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241201090916&v=2.18.0.post9+e462414">39607800</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae623>10.1093/eurheartj/ehae623</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39607800</guid>
<pubDate>Thu, 28 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Angelo Oliva</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:date>2024-11-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Handle with care, proceed with caution: do frail patients presenting with acute coronary syndrome benefit from revascularization?</dc:title>
<dc:identifier>pmid:39607800</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae623</dc:identifier>
</item>
<item>
<title>Acetylation alchemy: how Nat10 shapes vascular health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39607798/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241201090916&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 28:ehae822. doi: 10.1093/eurheartj/ehae822. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39607798/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241201090916&v=2.18.0.post9+e462414">39607798</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae822>10.1093/eurheartj/ehae822</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39607798</guid>
<pubDate>Thu, 28 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Timothy Warwick</dc:creator>
<dc:creator>Leo Kurian</dc:creator>
<dc:creator>Ralf P Brandes</dc:creator>
<dc:date>2024-11-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Acetylation alchemy: how Nat10 shapes vascular health</dc:title>
<dc:identifier>pmid:39607798</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae822</dc:identifier>
</item>
<item>
<title>Thoracic aortic disease: why sex matters</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39607796/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241201090916&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 28:ehae713. doi: 10.1093/eurheartj/ehae713. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39607796/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241201090916&v=2.18.0.post9+e462414">39607796</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae713>10.1093/eurheartj/ehae713</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39607796</guid>
<pubDate>Thu, 28 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Julia Dumfarth</dc:creator>
<dc:creator>Simone Gasser</dc:creator>
<dc:creator>Michael Grimm</dc:creator>
<dc:date>2024-11-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Thoracic aortic disease: why sex matters</dc:title>
<dc:identifier>pmid:39607796</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae713</dc:identifier>
</item>
<item>
<title>Pregnancy-related aortic pathology: where do we go from here?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39607795/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241201090916&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 28:ehae697. doi: 10.1093/eurheartj/ehae697. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39607795/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241201090916&v=2.18.0.post9+e462414">39607795</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae697>10.1093/eurheartj/ehae697</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39607795</guid>
<pubDate>Thu, 28 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Johanna A van der Zande</dc:creator>
<dc:creator>Mark R Johnson</dc:creator>
<dc:creator>Jolien W Roos-Hesselink</dc:creator>
<dc:date>2024-11-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Pregnancy-related aortic pathology: where do we go from here?</dc:title>
<dc:identifier>pmid:39607795</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae697</dc:identifier>
</item>
<item>
<title>Dissecting the effect of genetic variants on atherosclerosis: integrating bulk and single-cell transcriptomics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39607792/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241201090916&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 28:ehae489. doi: 10.1093/eurheartj/ehae489. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39607792/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241201090916&v=2.18.0.post9+e462414">39607792</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae489>10.1093/eurheartj/ehae489</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39607792</guid>
<pubDate>Thu, 28 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Elisa Duregotti</dc:creator>
<dc:creator>Manuel Mayr</dc:creator>
<dc:date>2024-11-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Dissecting the effect of genetic variants on atherosclerosis: integrating bulk and single-cell transcriptomics</dc:title>
<dc:identifier>pmid:39607792</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae489</dc:identifier>
</item>
<item>
<title>Myocardial infarction and low ambient temperature: does presence or absence of stenoses make a difference?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39607783/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241201090916&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 28:ehae820. doi: 10.1093/eurheartj/ehae820. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39607783/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241201090916&v=2.18.0.post9+e462414">39607783</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae820>10.1093/eurheartj/ehae820</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39607783</guid>
<pubDate>Thu, 28 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Magnus Bäck</dc:creator>
<dc:creator>Robin Hofmann</dc:creator>
<dc:date>2024-11-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Myocardial infarction and low ambient temperature: does presence or absence of stenoses make a difference?</dc:title>
<dc:identifier>pmid:39607783</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae820</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: Three is better than one for long-term risk prediction in healthy women</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39607765/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241201090916&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 28:ehae813. doi: 10.1093/eurheartj/ehae813. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39607765/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241201090916&v=2.18.0.post9+e462414">39607765</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae813>10.1093/eurheartj/ehae813</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39607765</guid>
<pubDate>Thu, 28 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Leonarda Galiuto</dc:creator>
<dc:creator>Giovanna Liuzzo</dc:creator>
<dc:date>2024-11-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: Three is better than one for long-term risk prediction in healthy women</dc:title>
<dc:identifier>pmid:39607765</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae813</dc:identifier>
</item>
<item>
<title>Endocarditis Therapy: The Move From Expert Opinion to Evidence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39603751/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241201090916&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 3;84(23):2305-2307. doi: 10.1016/j.jacc.2024.07.063.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39603751/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241201090916&v=2.18.0.post9+e462414">39603751</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.063>10.1016/j.jacc.2024.07.063</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39603751</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Brad Spellberg</dc:creator>
<dc:creator>Todd C Lee</dc:creator>
<dc:creator>Bassam Ghanem</dc:creator>
<dc:creator>Emily G McDonald</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Endocarditis Therapy: The Move From Expert Opinion to Evidence</dc:title>
<dc:identifier>pmid:39603751</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.063</dc:identifier>
</item>
<item>
<title>Length of Hospital Stay for Endocarditis Before and After the Partial Oral Treatment of Endocarditis Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39603750/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241201090916&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Following the POET trial, we found a reduction in median LOS of 8 days with no change in mortality and an associated lower rate of relapse of bacteremia.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 3;84(23):2293-2304. doi: 10.1016/j.jacc.2024.06.053.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The results from the POET (Partial Oral Treatment of left-sided Endocarditis) trial were published in August 2018 and established noninferiority of oral step-down antibiotic treatment in stabilized patients with infective endocarditis (IE). Data on length of hospital stay (LOS) and safety following the POET trial are warranted.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to examine changes in LOS and safety (mortality and relapse of bacteremia) before and after POET publication.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using Danish nationwide registries, patients with first-time IE caused by Streptococcus spp., Enterococcus faecalis, Staphylococcus aureus, or coagulase-negative staphylococci from 2012 to 2021 were identified. Median LOS was examined according to publication date (before and after September 2018). Mortality and relapse of bacteremia at 180 days of follow-up were examined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We identified 3,008 patients before POET publication (median age 72.8 years) and 1,740 after publication (median age 75.2 years) (P &lt; 0.0001). The median LOS decreased by 8 days: 41 days (Q1-Q3: 29-49 days) before POET publication and 33 days (Q1-Q3: 21-44 days) after POET publication (P &lt; 0.0001). Similar reductions in LOS were seen across microbiological etiologies and age groups. Reduction in LOS was most pronounced in nonsurgically treated patients. Mortality from IE admission to a maximum of 180 days' follow-up was 27.5% before POET publication and 28.3% after publication (P = 0.41). The bacteremia relapse rate within 180 days was 3.5% before POET publication and 1.6% after publication (P = 0.0002).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Following the POET trial, we found a reduction in median LOS of 8 days with no change in mortality and an associated lower rate of relapse of bacteremia.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39603750/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241201090916&v=2.18.0.post9+e462414">39603750</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.053>10.1016/j.jacc.2024.06.053</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39603750</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Lauge Østergaard</dc:creator>
<dc:creator>Mia Marie Pries-Heje</dc:creator>
<dc:creator>Marianne Voldstedlund</dc:creator>
<dc:creator>Niels Eske Bruun</dc:creator>
<dc:creator>Jonas Agerlund Povlsen</dc:creator>
<dc:creator>Nana Køber</dc:creator>
<dc:creator>Nikolaj Ihlemann</dc:creator>
<dc:creator>Christian Tuxen</dc:creator>
<dc:creator>Rasmus Hasselbalch</dc:creator>
<dc:creator>Peter Godsk Jørgensen</dc:creator>
<dc:creator>Anna Stahl</dc:creator>
<dc:creator>Eva Havers-Borgersen</dc:creator>
<dc:creator>Jeppe Kofoed Petersen</dc:creator>
<dc:creator>Claus Moser</dc:creator>
<dc:creator>Lars Køber</dc:creator>
<dc:creator>Kasper Iversen</dc:creator>
<dc:creator>Henning Bundgaard</dc:creator>
<dc:creator>Emil Loldrup Fosbøl</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Length of Hospital Stay for Endocarditis Before and After the Partial Oral Treatment of Endocarditis Trial</dc:title>
<dc:identifier>pmid:39603750</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.053</dc:identifier>
</item>
<item>
<title>Should We Let AI-ECG Algorithms Take Over the Grading of Diastolic Dysfunction in Mitral Regurgitation?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39603749/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241201090916&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 3;84(23):2290-2292. doi: 10.1016/j.jacc.2024.07.064.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39603749/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241201090916&v=2.18.0.post9+e462414">39603749</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.064>10.1016/j.jacc.2024.07.064</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39603749</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Márton Tokodi</dc:creator>
<dc:creator>Attila Kovács</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Should We Let AI-ECG Algorithms Take Over the Grading of Diastolic Dysfunction in Mitral Regurgitation?</dc:title>
<dc:identifier>pmid:39603749</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.064</dc:identifier>
</item>
<item>
<title>Using Electrocardiogram to Assess Diastolic Function and Prognosis in Mitral Regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39603748/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241201090916&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with significant MR, the grading of LVDF by AI-ECG is independently associated with all-cause mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 3;84(23):2278-2289. doi: 10.1016/j.jacc.2024.06.054.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The determination of left ventricular diastolic function (LVDF) in patients with significant (≥moderate) mitral regurgitation (MR) poses a complex challenge. We recently validated an artificial intelligence-enabled electrocardiogram (AI-ECG) algorithm to estimate LVDF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to evaluate the risk of all-cause mortality across AI-ECG LVDF-derived myocardial disease (MD) grades in MR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a retrospective study including all patients in the AI-ECG LVDF study testing group who underwent comprehensive transthoracic echocardiography confirming significant MR and electrocardiogram within 14 days of each other at the Mayo Clinic between September 2001 and April 2023. AI-ECG LVDF status was determined based on the index electrocardiogram and used to categorize patients into 3 stages of MD: MD-1, normal or grade 1 LVDF; MD-2, grade 2 LVDF; and MD-3, grade 3 LVDF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 4,019 patients with significant MR (mean age 69.8 years; 49.0% women), 1,175 (29.2%), 1,881 (46.8%), and 963 (24.0%) were classified by AI-ECG as MD-1, MD-2, and MD-3, respectively. The median mitral effective regurgitant orifice area was 26 mm<sup>2</sup> (Q1-Q3: 20-36 mm<sup>2</sup>). Over a median follow-up of 3.5 years, 1,636 (40.7%) patients died. In multivariable survival analysis adjusted for multiple risk factors, a higher diastolic function grade was independently associated with an increased death risk (MD-2, adjusted HR [aHR]: 1.99; 95% CI: 1.62-2.45; MD-3, aHR: 2.65; 95% CI: 2.11-3.34). These findings were consistent when accounting for mitral valve intervention and across various sensitivity and subgroup analyses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with significant MR, the grading of LVDF by AI-ECG is independently associated with all-cause mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39603748/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241201090916&v=2.18.0.post9+e462414">39603748</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.054>10.1016/j.jacc.2024.06.054</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39603748</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Gal Tsaban</dc:creator>
<dc:creator>Eunjung Lee</dc:creator>
<dc:creator>Samual Wopperer</dc:creator>
<dc:creator>Muhannad Abbasi</dc:creator>
<dc:creator>Hee Tae Yu</dc:creator>
<dc:creator>Garvan C Kane</dc:creator>
<dc:creator>Francisco Lopez-Jimenez</dc:creator>
<dc:creator>Sorin V Pislaru</dc:creator>
<dc:creator>Vuyisile T Nkomo</dc:creator>
<dc:creator>Abhishek J Deshmukh</dc:creator>
<dc:creator>Samuel J Asirvatham</dc:creator>
<dc:creator>Peter A Noseworthy</dc:creator>
<dc:creator>Paul A Friedman</dc:creator>
<dc:creator>Zachi Attia</dc:creator>
<dc:creator>Jae K Oh</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Using Electrocardiogram to Assess Diastolic Function and Prognosis in Mitral Regurgitation</dc:title>
<dc:identifier>pmid:39603748</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.054</dc:identifier>
</item>
<item>
<title>The "Ticking Clock" of Impending Diabetes: Cause for Concern or Window of Opportunity?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39603747/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241201090916&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 3;84(23):2260-2263. doi: 10.1016/j.jacc.2024.07.057.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39603747/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241201090916&v=2.18.0.post9+e462414">39603747</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.057>10.1016/j.jacc.2024.07.057</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39603747</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Laurence S Sperling</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The "Ticking Clock" of Impending Diabetes: Cause for Concern or Window of Opportunity?</dc:title>
<dc:identifier>pmid:39603747</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.057</dc:identifier>
</item>
<item>
<title>2-Fold More Cardiovascular Disease Events Decades Before Type 2 Diabetes Diagnosis: A Nationwide Registry Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39603746/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241201090916&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Individuals with T2DM had 2-fold more CVD events than matched comparisons starting 3 decades before T2DM diagnosis. This indicates that comprehensive preventive strategies may be initiated much earlier in individuals at risk of T2DM.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 3;84(23):2251-2259. doi: 10.1016/j.jacc.2024.06.050.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The risk of cardiovascular disease (CVD) is increased in individuals with type 2 diabetes mellitus (T2DM), but it remains uncertain how long an elevated CVD occurrence precedes diabetes diagnosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this study was to investigate CVD occurrence 30 years before, and 5 years after, T2DM diagnosis compared with matched comparisons.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This combined case-control and cohort study included all individuals diagnosed with T2DM in Denmark between 2010 and 2015, as well as general population comparisons matched by age and sex. CVD was defined as myocardial infarction or ischemic stroke. Conditional logistic regression was used to compute ORs for CVD prevalence in the 30-year period before T2DM diagnosis. Cox proportional hazards regression models were used to compute HRs for 5-year CVD incidence after T2DM diagnosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study included 127,092 individuals with T2DM and 381,023 matched comparisons. In the 30-year period before T2DM diagnosis, 14,179 (11.2%) T2DM individuals and 17,871 (4.7%) comparisons experienced CVD. CVD prevalence was higher in those with T2DM than the comparisons in the entire period before T2DM diagnosis, with ORs ranging from 2.18 (95% CI: 1.91-2.48) in the earliest period (25-30 years before diagnosis) to 2.96 (95% CI: 2.85-3.08) in the latest period (&lt;5 years before diagnosis). After T2DM diagnosis, 5-year CVD incidence was similarly increased in T2DM individuals vs comparisons (HR: 2.20; 95% CI: 2.12-2.27).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Individuals with T2DM had 2-fold more CVD events than matched comparisons starting 3 decades before T2DM diagnosis. This indicates that comprehensive preventive strategies may be initiated much earlier in individuals at risk of T2DM.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39603746/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241201090916&v=2.18.0.post9+e462414">39603746</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.050>10.1016/j.jacc.2024.06.050</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39603746</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Christine Gyldenkerne</dc:creator>
<dc:creator>Johnny Kahlert</dc:creator>
<dc:creator>Pernille G Thrane</dc:creator>
<dc:creator>Kevin K W Olesen</dc:creator>
<dc:creator>Martin B Mortensen</dc:creator>
<dc:creator>Henrik T Sørensen</dc:creator>
<dc:creator>Reimar W Thomsen</dc:creator>
<dc:creator>Michael Maeng</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>2-Fold More Cardiovascular Disease Events Decades Before Type 2 Diabetes Diagnosis: A Nationwide Registry Study</dc:title>
<dc:identifier>pmid:39603746</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.050</dc:identifier>
</item>
<item>
<title>Trellis tree-based analysis reveals stromal regulation of patient-derived organoid drug responses</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39603238/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241201090916&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 26:S0092-8674(24)01339-4. doi: 10.1016/j.cell.2024.11.023. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39603238/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241201090916&v=2.18.0.post9+e462414">39603238</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.023>10.1016/j.cell.2024.11.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39603238</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>María Ramos Zapatero</dc:creator>
<dc:creator>Alexander Tong</dc:creator>
<dc:creator>James W Opzoomer</dc:creator>
<dc:creator>Rhianna O'Sullivan</dc:creator>
<dc:creator>Ferran Cardoso Rodriguez</dc:creator>
<dc:creator>Jahangir Sufi</dc:creator>
<dc:creator>Petra Vlckova</dc:creator>
<dc:creator>Callum Nattress</dc:creator>
<dc:creator>Xiao Qin</dc:creator>
<dc:creator>Jeroen Claus</dc:creator>
<dc:creator>Daniel Hochhauser</dc:creator>
<dc:creator>Smita Krishnaswamy</dc:creator>
<dc:creator>Christopher J Tape</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Trellis tree-based analysis reveals stromal regulation of patient-derived organoid drug responses</dc:title>
<dc:identifier>pmid:39603238</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.023</dc:identifier>
</item>
<item>
<title>Ablation of persistent atrial fibrillation: lessons learnt from the CAPLA trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39602598/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241201090916&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 27:ehae832. doi: 10.1093/eurheartj/ehae832. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39602598/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241201090916&v=2.18.0.post9+e462414">39602598</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae832>10.1093/eurheartj/ehae832</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39602598</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Jayanthi N Koneru</dc:creator>
<dc:creator>Kenneth A Ellenbogen</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Ablation of persistent atrial fibrillation: lessons learnt from the CAPLA trial</dc:title>
<dc:identifier>pmid:39602598</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae832</dc:identifier>
</item>
<item>
<title>Long-Term Aspirin vs Clopidogrel After Coronary Stenting by Bleeding Risk and Procedural Complexity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39602157/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241201090916&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this study, in patients who experienced PCI and were event-free during 6 to 18 months of DAPT, the beneficial impact of clopidogrel monotherapy over aspirin monotherapy was consistent, regardless of bleeding risk and/or PCI complexity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 27. doi: 10.1001/jamacardio.2024.4030. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Antiplatelet monotherapy in the chronic maintenance period for patients with high bleeding risk (HBR) and those who have undergone complex percutaneous coronary intervention (PCI) has not yet been explored.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To compare clopidogrel vs aspirin monotherapy in patients with HBR and/or PCI complexity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of the multicenter HOST-EXAM Extended study, an open-label trial conducted across 37 sites in South Korea, enrolled patients from 2014 to 2018 with up to 5.9 years of follow-up. The analysis was conducted from February to November 2023. Patients who maintained dual antiplatelet therapy (DAPT) event-free for 6 to 18 months following PCI were included.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Patients were randomized to receive either clopidogrel or aspirin in a 1:1 ratio. Those with sufficient data to assess HBR or complex PCI were analyzed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Coprimary end points were thrombotic composite end point (cardiovascular death, nonfatal myocardial infarction, stroke, readmission due to acute coronary syndrome, and definite/probable stent thrombosis) and any bleeding (Bleeding Academic Research Consortium type 2 to 5).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 3974 patients included (mean [SD] age, 63.4 [10.7] years; 2976 male [74.9%]), 866 had HBR (21.8%), and 849 underwent complex PCI (21.4%). Clopidogrel as compared with aspirin was associated with lower rates of thrombotic and bleeding events regardless of HBR and/or PCI complexity. For the thrombotic composite end point, the hazard ratio (HR) was 0.75 (95% CI, 0.53-1.04) among HBR vs 0.62 (95% CI, 0.48-0.80) among patients without HBR (P for interaction = 0.38) and 0.49 (95% CI, 0.32-0.77) among patients with complex PCI vs 0.74 (95% CI, 0.59-0.92) among patients with noncomplex PCI (P for interaction = 0.12). The reduction in bleeding by clopidogrel compared with aspirin was consistent among both patients with HBR (HR, 0.82; 95% CI, 0.56-1.21) and patients without HBR (HR, 0.58; 95% CI, 0.40-0.85; P for interaction = 0.20) and among patients undergoing complex PCI (HR, 0.79; 95% CI, 0.47-1.33) vs noncomplex PCI (HR, 0.68; 95% CI, 0.50-0.93; P for interaction = 0.62).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this study, in patients who experienced PCI and were event-free during 6 to 18 months of DAPT, the beneficial impact of clopidogrel monotherapy over aspirin monotherapy was consistent, regardless of bleeding risk and/or PCI complexity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02044250.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39602157/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241201090916&v=2.18.0.post9+e462414">39602157</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4030>10.1001/jamacardio.2024.4030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39602157</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Jeehoon Kang</dc:creator>
<dc:creator>Jaewook Chung</dc:creator>
<dc:creator>Kyung Woo Park</dc:creator>
<dc:creator>Jang-Whan Bae</dc:creator>
<dc:creator>Huijin Lee</dc:creator>
<dc:creator>Doyeon Hwang</dc:creator>
<dc:creator>Han-Mo Yang</dc:creator>
<dc:creator>Kyoo-Rok Han</dc:creator>
<dc:creator>Keon-Woong Moon</dc:creator>
<dc:creator>Ung Kim</dc:creator>
<dc:creator>Moo-Yong Rhee</dc:creator>
<dc:creator>Doo-Il Kim</dc:creator>
<dc:creator>Song-Yi Kim</dc:creator>
<dc:creator>Sung-Yun Lee</dc:creator>
<dc:creator>Seung Uk Lee</dc:creator>
<dc:creator>Sang-Wook Kim</dc:creator>
<dc:creator>Seok Yeon Kim</dc:creator>
<dc:creator>Jung-Kyu Han</dc:creator>
<dc:creator>Eun-Seok Shin</dc:creator>
<dc:creator>Bon-Kwon Koo</dc:creator>
<dc:creator>Hyo-Soo Kim</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Long-Term Aspirin vs Clopidogrel After Coronary Stenting by Bleeding Risk and Procedural Complexity</dc:title>
<dc:identifier>pmid:39602157</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4030</dc:identifier>
</item>
<item>
<title>The FINE ART of Interpreting Health Status Benefits in Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39601741/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241201090916&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 26:S0735-1097(24)10293-8. doi: 10.1016/j.jacc.2024.10.095. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39601741/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241201090916&v=2.18.0.post9+e462414">39601741</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.095>10.1016/j.jacc.2024.10.095</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39601741</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>Suzanne V Arnold</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The FINE ART of Interpreting Health Status Benefits in Clinical Trials</dc:title>
<dc:identifier>pmid:39601741</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.095</dc:identifier>
</item>
<item>
<title>Enhanced Parkin-mediated mitophagy mitigates adverse left ventricular remodelling after myocardial infarction: role of PR-364</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39601359/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241201090916&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study demonstrates the therapeutic potential of targeting Parkin-mediated mitophagy using PR-364 to protect surviving cardiac tissue post-MI from progression to HF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 27:ehae782. doi: 10.1093/eurheartj/ehae782. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Almost 30% of survivors of myocardial infarction (MI) develop heart failure (HF), in part due to damage caused by the accumulation of dysfunctional mitochondria. Organelle quality control through Parkin-mediated mitochondrial autophagy (mitophagy) is known to play a role in mediating protection against HF damage post-ischaemic injury and remodelling of the subsequent deteriorated myocardium.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This study has shown that a single i.p. dose (2 h post-MI) of the selective small molecule Parkin activator PR-364 reduced mortality, preserved cardiac ejection fraction, and mitigated the progression of HF. To reveal the mechanism of PR-364, a multi-omic strategy was deployed in combination with classical functional assays using in vivo MI and in vitro cardiomyocyte models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In vitro cell data indicated that Parkin activation by PR-364 increased mitophagy and mitochondrial biogenesis, enhanced adenosine triphosphate production via improved citric acid cycle, altered accumulation of calcium localization to the mitochondria, and initiated translational reprogramming with increased expression of mitochondrial translational proteins. In mice, PR-364 administered post-MI resulted in widespread proteome changes, indicating an up-regulation of mitochondrial metabolism and mitochondrial translation in the surviving myocardium.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study demonstrates the therapeutic potential of targeting Parkin-mediated mitophagy using PR-364 to protect surviving cardiac tissue post-MI from progression to HF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39601359/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241201090916&v=2.18.0.post9+e462414">39601359</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae782>10.1093/eurheartj/ehae782</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39601359</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Lizhuo Ai</dc:creator>
<dc:creator>Juliana de Freitas Germano</dc:creator>
<dc:creator>Chengqun Huang</dc:creator>
<dc:creator>Marianne Aniag</dc:creator>
<dc:creator>Savannah Sawaged</dc:creator>
<dc:creator>Jon Sin</dc:creator>
<dc:creator>Reetu Thakur</dc:creator>
<dc:creator>Deepika Rai</dc:creator>
<dc:creator>Christopher Rainville</dc:creator>
<dc:creator>David E Sterner</dc:creator>
<dc:creator>Yang Song</dc:creator>
<dc:creator>Honit Piplani</dc:creator>
<dc:creator>Suresh Kumar</dc:creator>
<dc:creator>Tauseef R Butt</dc:creator>
<dc:creator>Robert M Mentzer</dc:creator>
<dc:creator>Aleksandr Stotland</dc:creator>
<dc:creator>Roberta A Gottlieb</dc:creator>
<dc:creator>Jennifer E Van Eyk</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Enhanced Parkin-mediated mitophagy mitigates adverse left ventricular remodelling after myocardial infarction: role of PR-364</dc:title>
<dc:identifier>pmid:39601359</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae782</dc:identifier>
</item>
<item>
<title>Percutaneous vs. surgical revascularization of non-ST-segment elevation myocardial infarction with multivessel disease: the SWEDEHEART registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39601339/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241201090916&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Coronary artery bypass grafting is associated with lower risks of mortality, MI, repeat revascularization, and heart failure in patients with NSTEMI, particularly in high-risk subgroups. However, its survival benefit lessens with shorter life expectancy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 27:ehae700. doi: 10.1093/eurheartj/ehae700. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The long-term outcomes of percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting (CABG) in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel disease remain debated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry was used to analyse 57 097 revascularized patients with NSTEMI with multivessel disease in Sweden from January 2005 to June 2022. The primary endpoint was all-cause mortality, encompassing both in-hospital and long-term mortality; the secondary endpoints included myocardial infarction (MI), stroke, new revascularization, and heart failure. Multilevel logistic regression with follow-up time as a log-transformed offset variable and double-robust adjustment with the instrumental variable method were applied to control for known and unknown confounders.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Percutaneous coronary intervention was the primary therapy in 42 190 (73.9%) patients, while 14 907 (26.1%) received CABG. Percutaneous coronary intervention patients were generally older with more prior cardiovascular events, whereas CABG patients had higher incidences of diabetes, hypertension, left main and three-vessel disease, and reduced ejection fraction. Over a median follow-up of 7.1 years, PCI was associated with higher risks of death [adjusted odds ratio (aOR) 1.67; 95% confidence interval (CI) 1.54-1.81] and MI (aOR 1.51; 95% CI 1.41-1.62) but there was no significant difference in stroke. Repeat revascularization was three times more likely to PCI (aOR 3.01; 95% CI 2.57-3.51), while heart failure risk was 15% higher (aOR 1.15; 95% CI 1.07-1.25). Coronary artery bypass grafting provided longer survival within 15 years, especially in patients under 70 years of age, with left main disease or left ventricular dysfunction, though this benefit diminished over shorter time horizons.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Coronary artery bypass grafting is associated with lower risks of mortality, MI, repeat revascularization, and heart failure in patients with NSTEMI, particularly in high-risk subgroups. However, its survival benefit lessens with shorter life expectancy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39601339/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241201090916&v=2.18.0.post9+e462414">39601339</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae700>10.1093/eurheartj/ehae700</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39601339</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Elmir Omerovic</dc:creator>
<dc:creator>Truls Råmunddal</dc:creator>
<dc:creator>Petur Petursson</dc:creator>
<dc:creator>Oskar Angerås</dc:creator>
<dc:creator>Araz Rawshani</dc:creator>
<dc:creator>Sandeep Jha</dc:creator>
<dc:creator>Kristofer Skoglund</dc:creator>
<dc:creator>Moman A Mohammad</dc:creator>
<dc:creator>Jonas Persson</dc:creator>
<dc:creator>Joakim Alfredsson</dc:creator>
<dc:creator>Robin Hofmann</dc:creator>
<dc:creator>Tomas Jernberg</dc:creator>
<dc:creator>Ole Fröbert</dc:creator>
<dc:creator>Anders Jeppsson</dc:creator>
<dc:creator>Emma C Hansson</dc:creator>
<dc:creator>Göran Dellgren</dc:creator>
<dc:creator>David Erlinge</dc:creator>
<dc:creator>Björn Redfors</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Percutaneous vs. surgical revascularization of non-ST-segment elevation myocardial infarction with multivessel disease: the SWEDEHEART registry</dc:title>
<dc:identifier>pmid:39601339</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae700</dc:identifier>
</item>





























</channel>
</rss>